Payment overview · 2025
General Payments
$382.13
14 reported records · 8 companies
Healthcare provider profile · identity verified
Marimer Rivera Vazquez, MD
Allopathic & Osteopathic Physicians|Family Medicine · MCALLEN, TX · NPI 1255651071
Verified facts
What the public records show
CMS Open Payments records show Marimer Rivera Vazquez, MD received $382.13 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $156.82 | 41.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $64.64 | 16.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.05 | 13.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.24 | 7.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.21 | 6.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.52 | 5.4% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $17.93 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.72 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $382.13 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $64.64 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.90 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.82 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 371 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 255 | 44 |
| Donepezil Hcl | Donepezil Hcl | 246 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 29 |
| Levetiracetam | Levetiracetam | 203 | 27 |
| Metformin Hcl | Metformin Hcl | 174 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 160 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 20 |
| Trazodone Hcl | Trazodone Hcl | 146 | 35 |
| Lisinopril | Lisinopril | 143 | 32 |
| Eliquis | Apixaban | 140 | 20 |
| Gabapentin | Gabapentin | 129 | 30 |
| Sertraline Hcl | Sertraline Hcl | 127 | 32 |
| Furosemide | Furosemide | 119 | 28 |
| Losartan Potassium | Losartan Potassium | 112 | 34 |
| Lactulose | Lactulose | 111 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 20 |
| Bumetanide | Bumetanide | 96 | 24 |
| Montelukast Sodium | Montelukast Sodium | 96 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 25 |
| Jardiance | Empagliflozin | 86 | 11 |
| Carvedilol | Carvedilol | 81 | 22 |
| Nifedipine Er | Nifedipine | 74 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 19 |
| Buspirone Hcl | Buspirone Hcl | 68 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 56 |
| Olanzapine | Olanzapine | 65 | 17 |
| Potassium Chloride | Potassium Chloride | 65 | 17 |
| Famotidine | Famotidine | 63 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 12 |
| Simvastatin | Simvastatin | 62 | 14 |
| Mirtazapine | Mirtazapine | 60 | 12 |
| Ozempic | Semaglutide | 59 | 15 |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Amantadine | Amantadine Hcl | 54 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Latanoprost | Latanoprost | 48 | 14 |
| Omeprazole | Omeprazole | 48 | 18 |
| Enalapril Maleate | Enalapril Maleate | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 26 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 30 |
| Finasteride | Finasteride | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 11 |
| Alprazolam | Alprazolam | 36 | 13 |
| Bethanechol Chloride | Bethanechol Chloride | 36 | suppressed |
| Baclofen | Baclofen | 35 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 27 |
| Prednisone | Prednisone | 35 | 20 |
| Azithromycin | Azithromycin | 33 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 12 |
| Tramadol Hcl | Tramadol Hcl | 32 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 11 |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | 11 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | 18 |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Cefdinir | Cefdinir | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Metolazone | Metolazone | 19 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 16 |
| Glipizide | Glipizide | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 17 | 14 |
| Celecoxib | Celecoxib | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Glucagon Emergency Kit | Glucagon | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | 11 |
| Spironolactone | Spironolactone | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Linezolid | Linezolid | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $382.13 · 14 records | AstraZeneca Pharmaceuticals LP | AUSTEDO XR, FARXIGA, HYQVIA, LOKELMA, Ozempic, QULIPTA, REXULTI, Rystiggo, UBRELVY, VYEPTI, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error